...
首页> 外文期刊>Urology >Accurate prediction of need for invasive treatment in alpha1-blocker treated patients with benign prostatic hyperplasia not possible: bootstrap validation analysis.
【24h】

Accurate prediction of need for invasive treatment in alpha1-blocker treated patients with benign prostatic hyperplasia not possible: bootstrap validation analysis.

机译:无法准确预测良性前列腺增生患者接受α1受体阻滞剂治疗的侵入性治疗的必要性:自举验证分析。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Frequently, statistically significant prognostic factors are reported in published studies with suggestions that disease management should be modified. However, the clinical relevance of such factors is rarely quantified. We evaluated the accuracy of predicting the need for invasive treatment among patients with benign prostatic hyperplasia treated conservatively with alpha1-blockers. METHODS: Information on eight prognostic factors was collected from 280 patients treated with alpha1-blockers. Using the proportional hazards regression coefficients, a risk score for retreatment was calculated for each patient. The analyses were repeated on 1000 groups of 280 patients sampled from the original case series. The results from these "bootstrap analyses" were compared with the original results. RESULTS: Three statistically significant predictors of retreatment were identified. The 20% of patients with the greatest risk score had an 18-month risk of retreatment of only 20% (this should ideally approach 100%). Analyses of less than one half of all the bootstrap samples resulted in the same three significant prognostic factors. The 20% of patients with the greatest risk score in each of the 1000 samples experienced a highly variable risk of retreatment of 0% to 42%. CONCLUSIONS: Strongly significant predictors for retreatment suggest the need for a change in disease management, but 4 of the 5 high-risk patients would be overtreated with a modified policy. The subclassification of patients with a relatively low risk and high risk of retreatment appeared far from accurate. Internal validation procedures may warn against the invalid translation of statistical significance into clinical relevance.
机译:目的:通常,已发表的研究报告了统计学上重要的预后因素,并建议应修改疾病管理。但是,此类因素的临床相关性很少量化。我们评估了用α1受体阻滞剂保守治疗的良性前列腺增生患者预测是否需要介入治疗的准确性。方法:从280例接受α1受体阻滞剂治疗的患者中收集了八个预后因素的信息。使用比例风险回归系数,为每位患者计算出再次治疗的风险评分。对从原始病例系列中抽取的280位患者的1000组进行了重复分析。这些“自举分析”的结果与原始结果进行了比较。结果:确定了三个统计学意义上的再治疗预测因素。风险评分最高的20%患者的18个月再治疗风险仅为20%(理想情况下应接近100%)。少于所有引导程序样本的一半的分析导致相同的三个重要预后因素。在1000个样本中,风险分数最高的20%的患者接受再治疗的风险介于0%至42%之间。结论:强烈的再治疗预测指标提示需要改变疾病管理,但是5例高危患者中有4例将通过修改后的政策进行过度治疗。相对低风险和高再治疗风险的患者的亚分类似乎远远不够准确。内部验证程序可能会警告不要将统计意义转换为临床相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号